Sociedad Americana de Hirudoterapia

Structural biology of factor VIIa/tissue factor initiated coagulation.

Review published in Frontiers in bioscience (Landmark edition) (2012)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosVadivel et al. · Frontiers in bioscience (Landmark edition), 2012

Abstract

Factor VII (FVII) consists of an N-terminal gamma-carboxyglutamic acid domain followed by two epidermal growth factor-like (EGF1 and EGF2) domains and the C-terminal protease domain. Activation of FVII results in a two-chain FVIIa molecule consisting of a light chain (Gla-EGF1-EGF2 domains) and a heavy chain (protease domain) held together by a single disulfide bond. During coagulation, the complex of tissue factor (TF, a transmembrane glycoprotein) and FVIIa activates factor IX (FIX) and factor X (FX). FVIIa is structurally "zymogen-like" and when bound to TF, it is more "active enzyme-like." FIX and FX share structural homology with FVII. Three structural biology aspects of FVIIa/TF are presented in this review. One, regions in soluble TF (sTF) that interact with FVIIa as well as mapping of Ca2+, Mg2+, Na+ and Zn2+ sites in FVIIa and their functions; two, modeled interactive regions of Gla and EGF1 domains of FXa and FIXa with FVIIa/sTF; and three, incompletely formed oxyanion hole in FVIIa/sTF and its induction by substrate/inhibitor. Finally, an overview of the recognition elements in TF pathway inhibitor is provided.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsBinding SitesBlood CoagulationBlood Coagulation FactorsCationsFactor VIIaHumansLipoproteinsModels, MolecularMultiprotein ComplexesProtein FoldingProtein Interaction Domains and MotifsThromboplastin

Resumen

Factor VII (FVII) consists of an N-terminal gamma-carboxyglutamic acid domain followed by two epidermal growth factor-like (EGF1 and EGF2) domains and the C-terminal protease domain. Activation of FVII results in a two-chain FVIIa molecule consisting of a light chain (Gla-EGF1-EGF2 domains) and a...

Por qué esto importa para la hirudoterapia

This review covered structural biology aspects of the factor VIIa/tissue factor complex, including mapping of metal-binding sites (Ca2+, Mg2+, Na+, Zn2+), modeled interactive regions of FXa and FIXa with FVIIa/sTF, and the incompletely formed oxyanion hole, with an overview of TFPI recognition elements. The relevance to ASH is minimal — the abstract addresses coagulation factor structure and function but involves no leeches, hirudin, or leech secretome components. Caveat: no leech involvement; indirect relevance as general coagulation biochemistry background only.

Citación

Structural biology of factor VIIa/tissue factor initiated coagulation.

Vadivel et al. · Frontiers in bioscience (Landmark edition), 2012

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.